Back to top
more

Lyell Immunopharma (LYEL)

(Delayed Data from NSDQ)

$2.61 USD

2.61
790,993

-0.06 (-2.25%)

Updated May 21, 2024 04:00 PM ET

After-Market: $2.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 248)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know

by Zacks Equity Research

Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 90%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 90% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Lyell Immunopharma (LYEL) Climb 93% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 93.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Biotech ETF Tops in June: 5 Stocks That Outperform

by Sweta Killa

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

by Zacks Equity Research

Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised

by Zacks Equity Research

JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.

Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 341%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 341.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.